Neumora Therapeutics reported that navacaprant failed to achieve statistical significance in two additional Phase 3 trials for major depressive disorder, Koastal-2 and Koastal-3. With the clean sweep of late-stage misses, the company said it would discontinue development of the program and prepare to cut 35% of its staff. In the trials, Neumora reported navacaprant did not significantly outperform placebo on the change in Montgomery–Åsberg Depression Rating Scale (MADRS) scores by week 6; in Koastal-3, placebo performed better on the depression score measure. The company said it expects the reorganization to deliver $10 million in annual savings and extend its cash runway into the third quarter of 2027. The update narrows the pipeline to other late-stage and early programs, including NMRA-511 for Alzheimer’s disease agitation, NMRA-898 for schizophrenia, and NMRA-215 in obesity.